Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC

September 20, 2017
H. Jack West, MD

H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).